Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
Public ClinicalTrials.gov record NCT02796651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
Study identification
- NCT ID
- NCT02796651
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 132 participants
Conditions and interventions
Conditions
Interventions
- Formoterol fumarate (6 μg) Drug
- Formoterol furmarate (20 μg) Drug
- Placebo for formoterol fumarate Drug
- Formoterol fumarate (12 μg) Drug
- Formoterol fumarate (40 μg) Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 130 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2016
- Primary completion
- Dec 6, 2016
- Completion
- Dec 6, 2016
- Last update posted
- Feb 6, 2018
2016
United States locations
- U.S. sites
- 20
- U.S. states
- 9
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Glendale | Arizona | 85306 | — |
| Research Site | Phoenix | Arizona | 85006 | — |
| Research Site | Tempe | Arizona | 85283 | — |
| Research Site | Celebration | Florida | 34747 | — |
| Research Site | Clearwater | Florida | 33756 | — |
| Research Site | DeLand | Florida | 32720 | — |
| Research Site | Orlando | Florida | 32825 | — |
| Research Site | Lawrenceville | Georgia | 30046 | — |
| Research Site | St Louis | Missouri | 63141 | — |
| Research Site | Las Vegas | Nevada | 89102 | — |
| Research Site | Charlotte | North Carolina | 28207 | — |
| Research Site | Gastonia | North Carolina | 28054 | — |
| Research Site | Medford | Oregon | 97504 | — |
| Research Site | Portland | Oregon | 97202 | — |
| Research Site | Easley | South Carolina | 29640 | — |
| Research Site | Greenville | South Carolina | 29615 | — |
| Research Site | Rock Hill | South Carolina | 29372 | — |
| Research Site | Spartanburg | South Carolina | 29303 | — |
| Research Site | Boerne | Texas | 78006 | — |
| Research Site | Killeen | Texas | 76543 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02796651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2018 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02796651 live on ClinicalTrials.gov.